AD-1652 6-11 YEARS

Improvement after the first dose,
as measured at WEEK 2
(≈9% vs ≈3%; P=0.0097)

Percentage of patients
achieving ≥4-point
reduction in Peak
Pruritus NRS

Weeks

61%

54%

≈4.5x as many
patients

13%

12%

DUPIXENT 300 mg Q4W + TCS
(<30 kg, n=61)^c DUPIXENT 200 mg Q2W + TCS
(≥30 kg, n=59)^d Placebo + TCS
(<30 kg, n=61) Placebo + TCS
(≥30 kg, n=62)

^aFull Analysis Set includes all subjects randomized.¹

^bIn the primary analyses of the efficacy endpoints, subjects who received rescue treatment or with missing data were considered nonresponders.¹

^cAt Day 1, subjects (baseline weight <30 kg) received 600 mg of DUPIXENT.¹

^dAt Day 1, subjects (baseline weight ≥30 kg) received 400 mg of DUPIXENT.¹

Explore more Peak Pruritus NRS efficacy results

How is the itch endpoint (Peak Pruritus NRS) assessed?

Peak Pruritus NRS assesses the average itch intensity over the previous 24 hours⁴

It is a patient-reported measure that uses a 0- to 10-point scale, with which patients are asked:

“On a scale of 0 to 10, how would you rate your itch overall (on average) during the previous 24 hours?”

0

None

0 - NONE

10

The Worst
Imaginable

10 - THE WORST
IMAGINABLE

A reduction of at least 4 points in Peak Pruritus NRS from baseline is a clinically meaningful change.¹

READY TO
PRESCRIBE
DUPIXENT?